.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD22_MetforminAndEvogliptin.MetforminAndEvogliptin .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD22_MetforminAndEvogliptin.MetforminAndEvogliptin| name: | MetforminAndEvogliptin | |
| ATC code: | A10BD22 | route: | oral |
| compartments: | 1 | |
| dosage: | 1000 | mg |
| volume of distribution: | 80 | L |
| clearance: | 66 | L/h |
| other parameters in model implementation | ||
Metformin and evogliptin is a fixed-dose combination oral antidiabetic medication. Metformin is a biguanide that decreases hepatic glucose production and increases insulin sensitivity, while evogliptin is a DPP-4 inhibitor that increases incretin levels, thereby promoting glycemic control. This combination is used to manage type 2 diabetes mellitus in adults, and is approved in some countries for clinical use.
Estimated pharmacokinetic parameters for typical adult (age 18-65 years) with type 2 diabetes mellitus, assuming no significant renal or hepatic impairment. No published population PK models specific to metformin/evogliptin FDC as of June 2024. Estimates based on available PK data for single compounds.